Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98


Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines.

Lantuéjoul S, Constantin B, Drabkin H, Brambilla C, Roche J, Brambilla E.

J Pathol. 2003 Jul;200(3):336-47.


Semaphorin SEMA3F and VEGF have opposing effects on cell attachment and spreading.

Nasarre P, Constantin B, Rouhaud L, Harnois T, Raymond G, Drabkin HA, Bourmeyster N, Roche J.

Neoplasia. 2003 Jan-Feb;5(1):83-92.


Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells.

Kusy S, Nasarre P, Chan D, Potiron V, Meyronet D, Gemmill RM, Constantin B, Drabkin HA, Roche J.

Neoplasia. 2005 May;7(5):457-65.


Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor.

Wei LH, Kuo ML, Chen CA, Cheng WF, Cheng SP, Hsieh FJ, Hsieh CY.

Gynecol Oncol. 2001 Jul;82(1):49-56.


Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion.

Nasarre P, Kusy S, Constantin B, Castellani V, Drabkin HA, Bagnard D, Roche J.

Neoplasia. 2005 Feb;7(2):180-9.


Frequent expression of the vascular endothelial growth factor in human non-small-cell lung cancers.

Takahama M, Tsutsumi M, Tsujiuchi T, Kido A, Okajima E, Nezu K, Tojo T, Kushibe K, Kitamura S, Konishi Y.

Jpn J Clin Oncol. 1998 Mar;28(3):176-81.


Human semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns.

Sekido Y, Bader S, Latif F, Chen JY, Duh FM, Wei MH, Albanesi JP, Lee CC, Lerman MI, Minna JD.

Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4120-5.


Semaphorin 3A-vascular endothelial growth factor-165 balance mediates migration and apoptosis of neural progenitor cells by the recruitment of shared receptor.

Bagnard D, Vaillant C, Khuth ST, Dufay N, Lohrum M, Puschel AW, Belin MF, Bolz J, Thomasset N.

J Neurosci. 2001 May 15;21(10):3332-41.


Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux.

Cohen AJ, Bunn PA, Franklin W, Magill-Solc C, Hartmann C, Helfrich B, Gilman L, Folkvord J, Helm K, Miller YE.

Cancer Res. 1996 Feb 15;56(4):831-9.


Isolation of the human semaphorin III/F gene (SEMA3F) at chromosome 3p21, a region deleted in lung cancer.

Xiang RH, Hensel CH, Garcia DK, Carlson HC, Kok K, Daly MC, Kerbacher K, van den Berg A, Veldhuis P, Buys CH, Naylor SL.

Genomics. 1996 Feb 15;32(1):39-48.


hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors.

Jiang SX, Kameya T, Asamura H, Umezawa A, Sato Y, Shinada J, Kawakubo Y, Igarashi T, Nagai K, Okayasu I.

Mod Pathol. 2004 Feb;17(2):222-9.


ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells.

Clarhaut J, Gemmill RM, Potiron VA, Ait-Si-Ali S, Imbert J, Drabkin HA, Roche J.

Neoplasia. 2009 Feb;11(2):157-66.


Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer.

Yamaji H, Iizasa T, Koh E, Suzuki M, Otsuji M, Chang H, Motohashi S, Yokoi S, Hiroshima K, Tagawa M, Nakayama T, Fujisawa T.

Cancer Immunol Immunother. 2004 Sep;53(9):786-92. Epub 2004 Jun 4.


Angiogenesis and phenotypic alteration of alveolar capillary endothelium in areas of neoplastic cell spread in primary lung adenocarcinoma.

Jin E, Ghazizadeh M, Fujiwara M, Nagashima M, Shimizu H, Ohaki Y, Arai S, Gomibuchi M, Takemura T, Kawanami O.

Pathol Int. 2001 Sep;51(9):691-700.


High expression of Met/hepatocyte growth factor receptor suppresses tumorigenicity in NCI-H1264 lung carcinoma cells.

To C, Seiden I, Liu N, Wigle D, Tsao MS.

Exp Cell Res. 2002 Feb 1;273(1):45-53.


Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma.

Ng IO, Poon RT, Lee JM, Fan ST, Ng M, Tso WK.

Am J Clin Pathol. 2001 Dec;116(6):838-45.

Items per page

Supplemental Content

Write to the Help Desk